Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Perfusion
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ortolano, G. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ortolano, G. A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Potential for reduction in morbidity and cost with total leucocyte control for cardiac surgery

Girolamo A Ortolano

Pall Corporation, East Hills, New York

The economics of health care in the USA and abroad has caused a shift in the focus on therapeutic interventions that transcend issues of safety and clinical efficacy. Now, cost justification is emerging as a major consideration to influence clinical practice. This brief review of the medical literature attempts to identify leucocyte-mediated adverse reactions that develop in open-heart surgery, quantify the costs incurred to manage such reactions and infer the savings that may accrue by controlling the burden of leucocytes presented to the open-heart surgical patient using commercially available leucocyte reducing filtration technology.

Perfusion, Vol. 10, No. 5, 283-290 (1995)
DOI: 10.1177/026765919501000502
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 PerfusionHome page
A H Olivencia-Yurvati, C A Ferrara, N Tierney, N Wallace, and R T Mallet
Strategic leukocyte depletion reduces pulmonary microvascular pressure and improves pulmonary status post-cardiopulmonary bypass
Perfusion, January 1, 2003; 18(1_suppl): 23 - 31.
[Abstract] [PDF]

Home page
 PerfusionHome page
G. A Ortolano, G. S Aldea, K. Lilly, P. O'Gara, J. D Alkon, F. Madera, T. Murad, C. P Altenbern, C. S Tritt, A. Capetandes, et al.
A review of leukofiltration in cardiac surgery: the time course of reperfusion injury may facilitate study design of anti-inflammatory effects
Perfusion, March 1, 2002; 17(2_suppl): 53 - 62.
[Abstract] [PDF]

Home page
 PerfusionHome page
S J Morris
Leukocyte reduction in cardiovascular surgery
Perfusion, September 1, 2001; 16(5): 371 - 380.
[PDF]

Home page
 PerfusionHome page
M. B Patel, K. S Kilgore, G. A Ortolano, C. L Gryboski, M. A Qureshi, P. Marcovitz, K. B Naylor, J. L Park, B. Wenz, N. Gikakis, et al.
Conditioned blood reperfusion during angioplasty (CoBRA) treatment of acute myocardial infarction
Perfusion, January 1, 2001; 16(1_suppl): 39 - 49.
[Abstract] [PDF]